JNJ
-
Johnson & Johnson to license novel oral assets, further strengthening commitment to atopic dermatitis
Johnson & Johnson gains an exclusive license to Kaken’s STAT6 program, including lead candidate KP-723
-
TOP PHARMAS BY 2024 PIPELINE SIZE
For more info, please visit https://www.drugtimes.cn/english-content
